Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Comment
  • Published:

Recognizing hypoxia in phaeochromocytomas and paragangliomas

Nature Reviews Endocrinology volume 16, pages 191–192 (2020)Cite this article

Subjects

Studies uncovering the cellular mechanisms of adaptation to varying oxygen levels were recognized with the 2019 Nobel Prize in Physiology or Medicine. Here, we focus on the remarkable parallels between the pathways regulating oxygen availability and those driving rare neuroendocrine tumours, phaeochromocytomas and paragangliomas, and discuss the translational implications of this connection.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Kaelin, W. G. Jr, Ratcliffe, P. J. & Semenza, G. L. Pathways for oxygen regulation and homeostasis: the 2016 Albert Lasker Basic Medical Research Award. JAMA 316, 1252–1253 (2016).

    Article  Google Scholar 

  2. Dahia, P. L. et al. A HIF1alpha regulatory loop links hypoxia and mitochondrial signals in pheochromocytomas. PLoS Genet. 1, 72–80 (2005).

    Article  CAS  Google Scholar 

  3. Hammarlund, E. U., von Stedingk, K. & Påhlman, S. Refined control of cell stemness allowed animal evolution in the oxic realm. Nat. Ecol. Evol. 2, 220–228 (2018).

    Article  Google Scholar 

  4. Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: the next generation. Cell 144, 646–74 (2011).

    Article  CAS  Google Scholar 

  5. Fishbein, L. et al. Comprehensive molecular characterization of pheochromocytoma and paraganglioma. Cancer Cell 31, 181–193 (2017).

    Article  CAS  Google Scholar 

  6. Zhuang, Z. et al. Somatic HIF2A gain-of-function mutations in paraganglioma with polycythemia. N. Engl. J. Med. 367, 922–930 (2012).

    Article  CAS  Google Scholar 

  7. Toledo, R. A. New HIF2alpha inhibitors: potential implications as therapeutics for advanced pheochromocytomas and paragangliomas. Endocr. Relat. Cancer 24, C9–C19 (2017).

    Article  CAS  Google Scholar 

  8. Saldana, M. J., Salem, L. E. & Travezan, R. High altitude hypoxia and chemodectomas. Hum. Pathol. 4, 251–263 (1973).

    Article  CAS  Google Scholar 

  9. Vaidya, A. et al. EPAS1 Mutations and paragangliomas in cyanotic congenital heart disease. N. Engl. J. Med. 378, 1259–1261 (2018).

    Article  Google Scholar 

  10. Courtney, K. D. et al. Phase I dose-escalation trial of PT2385, a first-in-class hypoxia-inducible factor-2alpha antagonist in patients with previously treated advanced clear cell renal cell carcinoma. J. Clin. Oncol. 36, 867–874 (2018).

    Article  CAS  Google Scholar 

Download references

Acknowledgements

P.L.M.D. is the Charles Tucker Hayes Chair in Oncology and is supported by the NIH (GM114102), Alex’s Lemonade Stand Foundation for Childhood Cancer Innovation Award (co-funded by Flashes of Hope and Northwest Mutual) and National Center for Advancing Translational Sciences (UL1 TR002645). R.A.T. holds a Miguel Servet-I research contract by Institute of Health Carlos III (ISCIII) of the Ministry of Economy (CP17/00199) and Competitiveness; is supported by an Olga Torres Foundation emerging researcher grant and by the Swiss Bridge Award for cancer immunotherapy research; and received a research grant from Novartis.

Author information

Authors and Affiliations

  1. Department of Medicine, Division of Hematology and Medical Oncology, Mays Cancer Center, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA

    Patricia L. M. Dahia

  2. CIBERONC, Gastrointestinal and Endocrine Tumors, Vall d’Hebron Institute of Oncology (VHIO), Centro Cellex, Barcelona, Spain

    Rodrigo A. Toledo

Authors
  1. Patricia L. M. Dahia
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Rodrigo A. Toledo
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Patricia L. M. Dahia or Rodrigo A. Toledo.

Ethics declarations

Competing interests

The authors declare no competing interests.

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Dahia, P.L.M., Toledo, R.A. Recognizing hypoxia in phaeochromocytomas and paragangliomas. Nat Rev Endocrinol 16, 191–192 (2020). https://doi.org/10.1038/s41574-020-0324-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41574-020-0324-1

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing